BioLife Solutions Adopts New Brand Identity

BioLife today announced the launch of its new corporate brand identity, redesigned logo, and website. The new brand identity was created to better reflect BioLife’s expanded portfolio of bioproduction tools and services. Todd Berard, Chief Marketing Officer, remarked, “We pursued a refreshed design that appropriately positions BioLife as the premier supplier of cell and gene…

Read More

BioLife Solutions Named one of the Fastest Growing Companies in North America on Deloitte’s 2019 Technology Fast 500™

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, recently announced that based on revenue growth from 2015 to 2018, it has been selected for inclusion on the Deloitte 2019 Technology Fast 500 list. Mike Rice, BioLife President and CEO, commented, “We…

Read More

BioLife Solutions to Acquire SAVSU Technologies

We’re Joining Forces! BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own.  The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU spans…

Read More


Implementation of Biopreservation Best Practices to Address a Critical Component of Cell & Gene Therapy Manufacturing Hosted by Cell and Gene Therapy Insights Implementation of best practices in formulation can directly address multiple process bottlenecks including: GMP compliance, minimizing freezing damage, support stability during storage and against transient warming events, support post-thaw stability, and excipient…

Read More

BioLife Solutions Announces Third Quarter 2018 Financial Results

Revenue increases 79% to a record $5.3 million; achieves net income of $1.2 million On November 8, 2018,  BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media products for cell and gene therapies, reported financial results and operational highlights for the three and nine months ended September 30, 2018. Revenue…

Read More

SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis

Temperature Sensitive Gene Therapy Protected by Cloud-Connected Smart Shipper and Cloud App for Real Time Distribution Visibility and Management On November 5, 2018, BioLife’s JV partner  SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform, announced that it is supplying its evo Smart…

Read More

New GE Life Sciences NK Cell White Paper Citing CryoStor

GE Life Sciences recently published the  white paper “Workflow for primary human NK cell isolation, xeno-free expansion,  harvest, and cryopreservation.” In it, they detail how challenging it is to obtain primary human NK cells at clinically relevant scale, and outline methods for workflow optimization and cryopreservation, utilizing CryoStor CS 10. For additional details or to…

Read More

BioPreservation Blog 8/8/2018

The number of applications for BioLife Solutions’ biopreservation reagents continues to grow, and we are pleased to highlight these newest citations: Habiel, D., Espindola, M., Coelho, A., & Hogaboam, C. Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice. The American Journal of Pathology 2018 Apr; 188(4): 891-903. doi: 10.1016/j.ajpath.2017.12.020 Habiel et. al. provided detailed methods for the creation…

Read More

Privacy Preference Center